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Introduction {#sec001}
============

Global estimates report 37 million people living with Human Immunodeficiency Virus (HIV), out of which about 26 million reside in Sub-Saharan (SSA) \[[@pone.0227779.ref001]\]. In Ghana, HIV prevalence among adults aged 15--49 years has declined from about 2.4% in 2013 to 1.6% in 2015 according to the World Bank report \[[@pone.0227779.ref002]\]. The life expectancy of HIV-infected patients has increased remarkably due to the use of antiretroviral therapy (ART) as a standard of care \[[@pone.0227779.ref003]--[@pone.0227779.ref005]\]. Unfortunately, long term ART use is associated with a wide spectrum of metabolic disturbances such as lipodystrophy, insulin resistance, and dyslipidemia \[[@pone.0227779.ref006]--[@pone.0227779.ref008]\]. Dyslipidemia is defined by elevations in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides and decreased high-density lipoprotein cholesterol (HDL-C).

The prevalence of dyslipidemia is reportedly higher in people living with HIV due to the effect of ART in Ghana \[[@pone.0227779.ref009]--[@pone.0227779.ref011]\]. The severity of dyslipidemia and the typical pattern of the lipid profile differ between and within the classes of antiretroviral (ARV) agents \[[@pone.0227779.ref012]\]. Lipid abnormalities have been reported to be frequently associated with HIV-infected individuals receiving protease inhibitors (PIs) and treatment-*naïve* HIV-infected patients, suggesting that HIV infection itself has a metabolic deleterious effect. Such reported side effects are not universal to all individuals on ART and may even vary in individuals with comparable ART, demographic, immunologic and virological characteristics \[[@pone.0227779.ref012]--[@pone.0227779.ref014]\]. This variability suggests that genetic factors and inherited predispositions may have a significant influence on the incidence of metabolic dysfunction \[[@pone.0227779.ref014], [@pone.0227779.ref015]\]. However, high HDL cholesterol and apolipoprotein A-I (*APOA-I*) have been directly associated with a better immunological outcome \[[@pone.0227779.ref016]\].

Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role in lipoprotein metabolism by mediating the uptake of cholesterol through the binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins. Mutations have been detected in different domains of the LDLR which have a distinct effect on LDLR structure and function \[[@pone.0227779.ref017], [@pone.0227779.ref018]\]. ATP-binding cassette A1(ABCA1) plays a critical role in the reverse cholesterol transport system. Mutation in ABCA1, that encodes this protein, along with genes responsible for their transcription regulation, can lead to abnormality in the metabolism of lipids \[[@pone.0227779.ref019], [@pone.0227779.ref020]\]. Apolipoprotein A5 (APOA5) has been shown to be a key regulator of plasma triglycerides and there are several SNPs associated with the APOA5 gene \[[@pone.0227779.ref021], [@pone.0227779.ref022]\]. Moreover, HIV-infected patients who harbor polymorphisms of the DSCAML1 (Down syndrome cell adhesion molecule like-1) gene exhibit a less favorable lipids profile \[[@pone.0227779.ref023], [@pone.0227779.ref024]\]. Current studies have suggested the relationship between the level of lipids and LDLR, ABCA1 APOA5, and DSCAML1 polymorphisms \[[@pone.0227779.ref015], [@pone.0227779.ref025]\].

Nevertheless, the exact mechanism of dyslipidemia is not fully understood but is most likely multifactorial with the genetic variation being shown to account for about 43--83% of the variability of plasma lipoprotein levels in a normal healthy population \[[@pone.0227779.ref016], [@pone.0227779.ref026]\]. Therefore, from the genetic perspective, HAART-associated hyperlipidemia could be under the influence of various forms of genetic polymorphisms, similar to that in non-HIV adults \[[@pone.0227779.ref027], [@pone.0227779.ref028]\]. Several single nucleotide polymorphisms (SNPs) that could account for a significant portion of the variation of blood lipoprotein concentrations have been identified through recent candidate gene studies and genome-wide association studies (GWAS)\[[@pone.0227779.ref015], [@pone.0227779.ref029]\].

The association between gene polymorphisms that may signal a predisposition to lipid abnormalities and clinical progression of HIV infection has not been thoroughly studied in Africa where the prevalence of HIV is on the increase. SNP prevalence differs by population and at present, the majority of the SNP-associated dyslipidemic studies among HIV patients have come from non-African countries with only a few of these studies emanating from Africa \[[@pone.0227779.ref015], [@pone.0227779.ref024], [@pone.0227779.ref030]\]. To the best of our knowledge, no published study has explored the genetic variants and markers associated with dyslipidemia in HIV-infected individuals on HAART in a Ghanaian population. This study, therefore, investigated the distribution of SNPs in four candidate genes that have had significant published lipid associations and their resultant associations with plasma lipid levels in Ghanaian HIV-infected patients on HAART. An understanding of the impact of host genetic factors on the prevalence of dyslipidemia in a cohort of HIV-infected individuals on HAART would promote interventions in the scaling up of treatment regimen.

Material and methods {#sec002}
====================

Study design and subjects {#sec003}
-------------------------

This study comprised HIV-1 infected patients who were on ART regimen for at least one year, with either a protease inhibitor (PI) or non-nucleoside reverse-transcriptase inhibitor (NNRTI) backbone without any history of dyslipidemia, hypertension, and diabetes. The NCEP-ATP III criteria were used to defined dyslipidemia among the HIV seropositive \[[@pone.0227779.ref031]\]. The HIV seropositive subjects were categorized into two groups; those with dyslipidemia (cases) and without dyslipidemia (controls). The adjuvant antiretroviral drugs were stavudine, lamivudine, and zidovudine with priorities for inclusion being given to participants who consented to undergo biochemical and genetic testing. Pregnant women, patients being treated with lipid-lowering drugs and those with neurological conditions that prevented them from understanding the concept of the research were excluded from the study.

Sample size determination {#sec004}
-------------------------

Based on previous report from a study conducted on the burden of dyslipidemia among adults in Ghanaian a population \[[@pone.0227779.ref032]\] and the lack of knowledge of the frequency of polymorphisms in the population, we assumed an expected proportion of 0.1 for exposure in HIV seropositive subjects with dyslipidemia, an assumed odds ratio of 2, a confidence interval of 95%, a power of identifying a significant difference between two groups, and 1:3 ratio, a total of 289 subjects were recruited.

Data collection and biochemical analysis {#sec005}
----------------------------------------

A structured questionnaire was administered to each patient to obtain demographic information. Details on ARVs, time of diagnosis, duration on ARVs, CD4 counts were obtained from the medical folders of the patients. Fasting blood samples were collected for the analysis of lipid parameters and genomic DNA.

Blood samples were taken after an overnight (12--14 hours) fast into EDTA tubes for biochemical analysis. Fasting lipid panel including total cholesterol (TC), HDL-cholesterol and triglycerides (TG) were measured using Flexor junior (Vital Scientific, Dieren, Netherlands) chemistry autoanalyzer. LDL-C was calculated from the Friedewald's formula, LDL-C = TC- (HDL-C- TG/2.2). Patient with triglycerides above 4.52 mmol/L was not included in the study since LDL-C was not directly measured and due to the deficit of the Friedewald's equation, which overestimates LDL-C levels when triglycerides are high. This is to reduce any bias that might affect the relationship found between LDL-C and dyslipidemia. The NCEP-ATP III criteria were used to define dyslipidemia as reduced HDL (\<1.03 mmol/L in males; \<1.29 mmol/L in females), raised TG ≥1.7 mmol/L, TC \>6.2 mmol/L and LDL-C \>3.37 mmol/L or specific treatment for such lipid abnormalities \[[@pone.0227779.ref031]\].

Anthropometric and hemodynamic measures {#sec006}
---------------------------------------

Anthropometric measures such as weight and height were performed using an automated weighing scale. Portable height rod stadiometers were used for height measurements to the nearest centimeter. Body mass index (BMI) was defined as weight (kg)/height (m)^2^. Blood pressure was measured using an automated sphygmomanometer (Omron M7 Intelli IT). Three consecutive readings of blood pressure measurements were taken from the patients' right arm and the mean of two closest values was recorded.

Single nucleotide polymorphisms selection and genotyping {#sec007}
--------------------------------------------------------

The four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) selected for this study have been shown in previous studies to be significantly associated with lipid serum abnormalities following a review of GWAS and PubMed reports of SNPs associated with dyslipidemia among HIV-infected individuals \[[@pone.0227779.ref024], [@pone.0227779.ref033]--[@pone.0227779.ref035]\]. Genomic DNA was isolated from EDTA-collected whole blood samples of study participants using the Qiagen midi kit prep as per manufacturer's protocol. Genotyping was carried out on isolated genomic DNA of study participants using a multiplex ligation detection reaction (LDR), a sequence-specific genotyping method that has been used efficiently in polymorphism typing and detection of mutations in disease genes \[[@pone.0227779.ref036]\]. Triplex multiplex reaction assays were setup with products being run on 10% polyacrylamide gel for LDR genotype observation (58 to 90 base pairs). The LDR products differed in sizes of about 8 base pairs for each triplex **([Fig 1](#pone.0227779.g001){ref-type="fig"})**. The runs were controlled with Amelogenin XY (AME XY) to determine a successful reaction and gender-confirming for study participants.

![A representative gel depicting a genotype assay using triplex ligation detection reaction.](pone.0227779.g001){#pone.0227779.g001}

Allele specific LDR products are assigned by color and size following 10% polyacrylamide gel electrophoresis. Each band as shown in the image represents a specific genotype of each allele. At the bottom of the gel are leftover LDR probes from the reaction mix as represented by shared common bands **([Fig 1](#pone.0227779.g001){ref-type="fig"}).**

Ethical consideration {#sec008}
---------------------

The study protocol was approved by the Committee of Human Publication and Research Ethics of the School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. All participants gave written informed consent and were assured that the information gathered was to be used strictly for research and academic purpose only. In addition, respondents were given the freedom to opt-out at any time they thought they could not continue with the study.

Data management and statistical analysis {#sec009}
----------------------------------------

The NCEP-ATP III criteria were used to defined dyslipidemia among the HIV seropositive \[[@pone.0227779.ref032]\]. The HIV seropositive subjects were categorized into two groups; those with dyslipidemia (cases) and without dyslipidemia (control). Microsoft Excel software was used to set up a database, and to avoid entry error, the double-entry method was used, and data were analyzed using SPSS version 25 and R program where appropriately. Parametric continuous were analyzed with a t-test and expressed as mean ± standard deviation (SD) after checking for normality with the Kolmogorov-Smirnov test.

ANOVA was used to compare continuous variables from more than two groups with Yates post-test, the chi-square test was to compare differences between more than three groups for categorical variables while Fisher exact was used to assess differences between two groups for categorical variables Allele frequencies were estimated by gene counting. Deviations in the genotype frequencies from the Hardy-Weinberg equilibrium (HWE) were tested using the chi-square (χ^2^) analysis. Initial univariate binary logistic models were performed to determine the association between SNPs and dyslipidemia, followed by adjusted multivariate binary logistic models controlling for age, gender, BMI, CD4 counts and duration of HIV infection. Adjusted multivariate binary logistic models were used also to identify SNPs independently associated with lipid abnormalities holding confounding variables constant. A p-value of less than 0.05 was considered statistically significant.

Results {#sec010}
=======

**[Table 1](#pone.0227779.t001){ref-type="table"}** shows a comparison of demographic, hemodynamic indices, lipid parameters, dyslipidemic indices between cases and control subjects. Dyslipidemia was found in 31.1% (90/289). A statistically significant difference between case and control subjects was observed with regards to age (p = 0.0328). There were more females than males in the study population (p\>0.05). The average duration of treatment among the subjects was 4 years. There were statistically significant differences between the case and control subjects in relation to CD4 counts (p = 0.0010) and BMI (p\<0.0001). The case subjects had significantly higher levels of TC (p\<0.000) LDL-C (p\<0.0001) and CR (p\<0.0001) compared to the control subjects. Compared to HIV seropositive subjects with dyslipidemia, those without dyslipidemia had significantly increased levels of HDL-C (0.7 ±0.3 vs. 1.2±0.5, p\<0.0001).

10.1371/journal.pone.0227779.t001

###### Comparison of the general characteristics of study participants.

![](pone.0227779.t001){#pone.0227779.t001g}

  Variables                                                       Cases (n = 90)   Controls (n = 199)   P-value
  --------------------------------------------------------------- ---------------- -------------------- ----------
  Age (years)                                                     40.9±10.8        39.2±2.0             0.0328
  Gender [^b^](#t001fn002){ref-type="table-fn"}                                                         0.7535
  Female                                                          73(81.1%)        157(78.9%)           
  Male                                                            17(18.9%)        42(21.1%)            
  Duration of treatment                                           4.3±2.6          4.2±2.9              0.7796
  CD4 counts                                                      420.7±28.9       410.6±21.2           0.0010
  **Blood pressure (mmHg)**                                                                             
  Systolic                                                        112.5±13.8       114.8±17.6           0.2739
  Diastolic                                                       79.9±7.6         81.5±8.6             0.2309
  Anthropometric indices                                                                                
  Weight (kg)                                                     76.9±13.8        76.6±14.5            0.8688
  Height (m)                                                      1.58±0.18        1.60±0.13            0.2861
  Body mass index (BMI) (kg/m^2^)                                 33.8±2.4         31.5±1.1             \<0.0001
  **Lipid parameters (mmol/L)**                                                                         
  Total Cholesterol                                               5.2±0.7          4.0±0.8              \<0.0001
  Triglycerides                                                   1.4±0.7          1.4±0.6              0.9999
  HDL-Cholesterol                                                 0.7±0.3          1.2±0.5              \<0.0001
  LDL-Cholesterol                                                 4.1±0.6          2.5±0.8              \<0.0001
  VLDL-Cholesterol                                                0.6±0.34         0.6±0.35             0.9999
  Coronary Risk                                                   10.5±0.3         6.2±4.8              \<0.0001
  **    Dyslipidemic indices**                                                                          
  High triglyceride [^b^](#t001fn002){ref-type="table-fn"}        8(8.9%)          26(13.1%)            0.4986
  High total cholesterol [^b^](#t001fn002){ref-type="table-fn"}   10(11.1%)        4(2.0%)              0.0184
  Low HDL-Cholesterol [^b^](#t001fn002){ref-type="table-fn"}      90(100.0%)       107(53.8%)           \<0.0001
  High LDL-Cholesterol [^b^](#t001fn002){ref-type="table-fn"}     90(100.0%)       14(7.0%)             \<0.0001

Cases: HIV seropositive with dyslipidemia, control: HIV seropositive without dyslipidemia

^b^Fisher exact test, Dyslipidemia is defined as the presence of at least one NCEP-ATP III criteria reduced HDL (\<1.03 mmol/L in males; \<1.29 mmol/L in females), raised TG ≥1.7 mmol/L, TC \>6.2 mmol/L and LDL-C \>3.37 mmol/L p\<0.05 is considered statistically significant.

**[Table 2](#pone.0227779.t002){ref-type="table"}** shows the frequency distribution of the genotypes and alleles of the four SNPs. The percentage of the population who had the rare homozygote alleles for rs6511720 (T/T), rs2066714 (G/G), and rs10892151 (T/T) and rs662799 (G/G) among the case subjects were 5 .5%, 14.4%, 6.6% and 10.0% whiles 2.0% 9.1%, 6.5% and 4.0% were observed among the control subjects. Statistically significant differences in allelic frequency were observed for DSCAML1 (p = 0.0008)and APOA5 (p = 0.0251) among case subjects, and ABCA1 (p = 0.0010) and DSCAML1 (p = 0.0084) among control subjects. Moreover, chi-square analysis reveals significant differences in the genetic frequencies of LDLR (p = 0.0387) and APOA5 (p = 0.0353) polymorphisms respectively.

10.1371/journal.pone.0227779.t002

###### Genotypic and allelic frequencies of polymorphisms of the Studied Population.

![](pone.0227779.t002){#pone.0227779.t002g}

  Polymorphisms                                   Cases      Controls                                    
  ----------------------------------------------- ---------- ---------- ------ ----------- ------ ------ ------------
  LDLR (rs6511720) G\>T                                      G          T                  G      T      **0.0387**
                                                             0.81       0.19               0.89   0.11   
  G/G                                             61(67.8)                     159(79.9)                 
  G/T                                             24(26.7)                     34(18.1)                  
  T/T                                             5(5.5)                       4(2.0)                    
  HWE-*P*[^¥^](#t002fn003){ref-type="table-fn"}              0.28184           0.1875                    
  ABCA1 (rs2066714) A\>G                                     G          A                  G      A      0.3876
                                                             0.73       0.27               0.78   0.22   
  G/G                                             13(14.4)                     18(9.1)                   
  A/G                                             23(25.6)                     53(26.6)                  
  A/A                                             54(60.0)                     128(64.3)                 
  HWE-*P*[^¥^](#t002fn003){ref-type="table-fn"}              0.0008            0.0010                    
  DSCAML1 (rs10892151) C\>T                                  C          T                  C      T      0.9585
                                                             0.8        0.2                0.81   0.19   
  C/C                                             60(66.7)                     136(68.3)                 
  C/T                                             24(26.7)                     50(25.2)                  
  T/T                                             6(6.6)                       13(6.5)                   
  HWE-*P*[^¥^](#t002fn003){ref-type="table-fn"}              0.1138            0.0084                    
  APOA5 (rs662799) A\>G                                      A          G                  A      G      0.0353
                                                             0.76       0.24               0.84   0.16   
  A/A                                             56(62.2)                     142(71.4)                 
  A/G                                             25(27.8)                     51(25.6)                  
  G/G                                             9(10.0)                      6(3.0)                    
  HWE-*P*[^¥^](#t002fn003){ref-type="table-fn"}              0.0251            0.1625                    

Cases: HIV seropositive with dyslipidemia, control: HIV seropositive without dyslipidemia, HWE-P: Hardy-Weinberg equation p-value

^\#^P-value represents chi-square test to compare genotype frequency between cases

^¥^P-values for Chi-squared test for variant allelic frequency based on HWE; If p\<0.05 means it not consistent with HWE

Total Cholesterol (TC) {#sec011}
----------------------

The case subjects who had the rare homozygous genotype for LDLR (p\<0.0001), ABAC1 (p = 0.0287) DSCAML1 (p = 0.0003) and APOA5 (p = 0.0151) had a significantly higher level of TC compared to the combined heterozygous and non-carriers' genotypes **\[[Table 3](#pone.0227779.t003){ref-type="table"}\].**

10.1371/journal.pone.0227779.t003

###### Comparison of lipid parameters among study participants based on polymorphisms.

![](pone.0227779.t003){#pone.0227779.t003g}

  Variables                             Cases                     Controls                                        
  ---------------------- -------------- ------------ ------------ -------------- --------- ------------ --------- ---------
  LDLR (rs6511720)                                                                                                
  G\>T                                                                                                            
  GG/GT                  5.0±0.6        1.4±0.6      0.7±0.3      4.0±0.5        3.9±0.8   1.4±0.8      1.4±0.5   2.4±0.8
  T/T                    6.6±1.0        2.1±1.8      0.6±0.4      5.5±0.6        4.5±1.4   1.6±0.6      1.1±0.5   2.7±1.2
  p-value                **\<0.0001**   **0.0178**   0.895        **\<0.0001**   0.1832    0.7018       0.2125    0.4866
  ABCA1 (rs2066714)                                                                                               
  A\>G                                                                                                            
  AA/AG                  5.1±0.7        1.3±0.7      0.6±0.3      4.1±0.1        3.8±0.9   1.4±0.9      1.2±0.6   2.4±0.8
  G/G                    5.5±0.8        1.8±0.7      0.8±0.4      4.4±0.6        4.2±1.1   1.4±0.06     1.1±0.4   2.7±0.9
  p-value                **0.0287**     0.1148       0.2213       0.0968         0.247     0.8847       0.4001    0.3085
  DSCAML1 (rs10892151)                                                                                            
      C\>T                                                                                                        
  CC/CT                  4.8±0.5        1.2±0.4      0.6±0.5      4.1±0.6        4.0±0.9   1.4±0.6      1.2±0.5   2.3±0.6
  T/T                    6.1±1.2        2.3±1.5      0.9±0.4      4.8±0.9        4.3±1.0   1.9±1.1      1.0±0.6   2.9±0.6
  p-value                **0.0003**     **0.0006**   0.1036       **0.0078**     0.1946    **0.0133**   0.3933    0.0665
  APOA5 (rs662799)                                                                                                
  A\>G                                                                                                            
  AA/AG                  5.0±0.2        1.4±0.7      0.6±0.3      4.2±0.6        4.1±0.7   1.5±0.7      1.2±0.4   2.5±0.8
  G/G                    5.6±0.9        1.3±0.6      0.9±0.2      4.5±0.8        4.4±1.2   1.7±0.9      1.0±0.6   2.8±0.9
  p-value                **0.0151**     0.7388       **0.0075**   0.1017         0.1563    0.3039       0.5685    0.2911

TC: Total cholesterol, TG: Triglyceride, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, Cases: HIV seropositive with dyslipidemia, Control: HIV seropositive without dyslipidemia, Data is presented as mean±standard deviation, T-test was performed to obtained p-values, p\<0.05 significant

Triglycerides (TG) {#sec012}
------------------

Statistically significant differences were observed in TG levels for DSCAML1(p = 0.0006) and LDLR (p = 0.0178) polymorphisms between homozygous rare genotype and heterozygous and non-carriers' genotypes among the case subjects. Similar patterns were observed for DSCAML1 polymorphisms (p = 0.0133) among the control subjects **\[[Table 3](#pone.0227779.t003){ref-type="table"}\].**

HDL Cholesterol (HDL-C) {#sec013}
-----------------------

There were significant differences in HDL-C levels with regards to APOA5 polymorphisms (p = 0.0075) in case subjects. Thus, the combined heterozygous and non-carriers genotype had high levels of HDL-C compared to the homozygous genotypes **\[[Table 3](#pone.0227779.t003){ref-type="table"}\].**

LDL Cholesterol (LDL-C) {#sec014}
-----------------------

There were significant increased LDL-C levels in the rare-allelic subjects for LDLR (p\<0.0001) and DSCAML1 (p = 0.0078) polymorphisms compared to participants with heterozygous and homogenous genotypes together among the case subjects **\[[Table 3](#pone.0227779.t003){ref-type="table"}\].**

Individuals with G/G genotype for APOA5 (rs662799) polymorphisms were significantly associated with an increased likelihood of developing dyslipidemia upon both univariate \[OR = 3.54, 95% CI(1.27--10.25; p = 0.0208)\] and multivariate \[OR = 2.38, 95% CI(1.06--6.54; p = 0.0093)\] logistic regression analyses holding other variables constant. A similar trend was observed for rare homozygous genotype for LDLR polymorphisms; however, no statistically significant association was noted \[**[Table 4](#pone.0227779.t004){ref-type="table"}**\].

10.1371/journal.pone.0227779.t004

###### Association between single nucleotide polymorphisms and the prevalence of dyslipidemia.

![](pone.0227779.t004){#pone.0227779.t004g}

  Variables              Dyslipidemia                                    
  ---------------------- ------------------- -------- ------------------ --------
  LDLR (rs6511720)                                                       
  GG/GT                  1                            1                  
  T/T                    2.87(0.83--9.50)    0.1427   2.23(0.61--8.18)   0.2260
  ABCA1 (rs2066714)                                                      
  GG/AG                  1                            1                  
  A/A                    1.70(0.81 3.57)     0.2171   1.56(0.68--3.57)   0.2910
  DSCAML1 (rs10892151)                                                   
  CC/CT                  1                            1                  
  T/T                    1.02(0.38--2.63)    0.8944   0.68(0.22--2.11)   0.5090
  APOA5 (rs662799)                                                       
  AA/AG                  1                            1                  
  G/G                    3.54(1.27--10.25)   0.0208   2.38((1.06--6.54   0.0093

Cases: HIV seropositive with dyslipidemia, Control: HIV seropositive without dyslipidemia, Odds ratio was calculated for each single nucleotide polymorphism using rs6511720-GG, rs2066714-GG, rs10892151-CC, and rs662799-AA genotypes as a referent genotype OR = Odds ratio, CI = Confidence interval. A multivariate logistic model was performed controlling for age, gender, duration of treatment, CD4 counts and BMI, p\<0.05 considered statistically significant

**[Table 5](#pone.0227779.t005){ref-type="table"}** shows the association between SNPs with lipid abnormalities after controlling for age, gender, duration of treatment, CD4 counts and BMI respectively. Individuals with the rare homozygous genotype of *ABCA1* (G/G) \[aOR = 10.7(1.3--88.7), p = 0.0280\] and *LDLR* (rs6511720) G\>T \[aOR = 61.2(7.6--493.4), p\<0.0001) were more likely to have high levels of TC levels. Moreover, subjects with T/T genotype of *APOA5* (G/G) polymorphism were associated with increased levels of LDL-C \[aOR **=** 2.2(1.4--6.0), p = 0.014\].

10.1371/journal.pone.0227779.t005

###### Association of SNPs with individual lipid abnormalities.

![](pone.0227779.t005){#pone.0227779.t005g}

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Variables                  High TC\                   High TG\         Low HDL-C\       High-LDL-C\
                             (mmol/L)                   (mmol/L)         (mmol/L)         (mmol/L
  -------------------------- -------------------------- ---------------- ---------------- -------------------------------------------------------
  LDLR (rs6511720) T/T       61.2 (7.6--493.4)^†\ ††^   0.9 (0.1--1.0)   0.9 (0.2--3.9)   2.7 (0.7--10.6)

  ABCA1 (rs2066714) G/G      10.7 (1.3--88.7) ^†^       1.8 (0.6--5.3)   1.3 (0.5--3.2)   1.7 (0.8--3.9)

  DSCAML1 (rs10892151) T/T   2.3 (0.3--17.2)            1.7 (0.5--6.2)   0.8 (0.3--4.8)   0.9 (0.3--2.8)

  APOA5 (rs662799) G/G       5.8 (0.8--44.9)            0.9 (0.2--4.6)   1.4 (0.4--4.8)   2.2 (1.4--6.0) [^†^](#t005fn002){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------------------------

TC = Total cholesterol, TG = Triglycerides, HDL-C = High Density Lipoprotein Cholesterol, LDL-C = Low Density Lipoprotein Cholesterol, Odds ratio was calculated for the rare recessive polymorphism of rs6511720, rs2066714, rs10892151 and rs662799 genotypes using a combination of carriers and homozygotes as a referent genotype, aOR = Adjusted odds ratio, CI = Confidence interval. A multivariate logistic model was performed controlling for age, gender, duration of treatment, CD4 counts and BMI

^†^ p\<0.05

^†\ ††^p\<0.0001, p\<0.05 = statistically significant

**[S1 Table](#pone.0227779.s002){ref-type="supplementary-material"}** shows the demographic, clinical and metabolic characteristics of participants stratified on the type of ART (NNRTI vs. PI). There were 3.5% (10/289) on PI-based treatment whiles 279 (96.4%) were on NNRTI-based treatment. No statistically significant association was observed between NNRTI AND PI- based treatment in relation to age (p = 0.2569), gender (p = 0.6929), duration of treatment (p = 0.2092), systolic (p = 0.7638) and diastolic pressure (p = 0.0865), weight (p = 0.2122), height (p = 0.7221) and BMI (0.6825) respectively. Seventy-five (15.6%) patients had hypertriglyceridemia, 24.9% had hypercholesterolemia and 71.9% had low HDL-C in relation to metabolic parameters. PI-based subjects had significantly higher levels of total cholesterol (6.09±0.56 vs. 4.34±0.96, p = 0.0001) and LDL cholesterol (4.60±0.55 vs. 2.95±1.16, p = 0.0001) and triglycerides (2.61±0.65 vs. 1.43±0.69, p = 0.0001) compared to NNRTI-based subjects.

Discussion {#sec015}
==========

Long term usage of ART has been implicated in several metabolic effects including dyslipidemia. However, this side effect varies among individuals on ART with comparable clinical and demographic characteristics. As such, inherited predispositions and genetic factors have been implicated in the cause of this metabolic alteration. The present study, therefore, assessed the prevalence of SNPs and their associations with dyslipidemia in HIV patients on ART in Ghana. Four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) reviewed from PubMed were analyzed for associations with dyslipidemia among HIV-infected individuals.

Several studies have shown the association between dyslipidemia and HIV patients on ART \[[@pone.0227779.ref037], [@pone.0227779.ref038]\]. The prevalence rate of dyslipidemia among HIV patients on ART in this current study was 31.1% with low HDL-C and high TC levels being the commonest lipid abnormalities. The observed prevalence of dyslipidemia is comparable to the range of reports from previous studies by Obirikorang et al.\[[@pone.0227779.ref009]\] and Ngala et al. \[[@pone.0227779.ref010]\] in Ghana and Kodogo et al. \[[@pone.0227779.ref010]\] in Zimbabwe. However, it is lower compared to 78.9% prevalence rate reported by Limas et al. \[[@pone.0227779.ref039]\] in a cross-sectional study among Brazilian HIV individuals on ART. Furthermore, our observed results for low HDL-C, high TC and LDL-C levels among HIV patients on ART are consistent with other studies \[[@pone.0227779.ref040], [@pone.0227779.ref041]\]. Results from the present study revealed that subjects who received PI-based treatment had significantly increased levels of TC, LDL cholesterol and triglycerides levels compared to the non-PI-based subjects. These findings are consistent with several case reports \[[@pone.0227779.ref042], [@pone.0227779.ref043]\] and cross-sectional studies \[[@pone.0227779.ref044], [@pone.0227779.ref045]\] which have reported that PI exposures are associated with hypercholesterolemia and hypertriglyceridemia.

Our study demonstrated that the presence of the homozygous recessive/mutant genes for *LDLR*, *ABCA1*, *DSCAML1* and *APOA5* genotypes among our study participants were very low \[[Table 2](#pone.0227779.t002){ref-type="table"}\]. Similar low frequencies in APOA5 and LDLR homozygotes mutant genes were reported by Lazzaretti et al. \[[@pone.0227779.ref015]\] in a cross-sectional study among HIV-infected patients on ART in the Brazilians population. Genome-wide associations studies have identified LDL-R SNP rs6511720 (G\>T), which is located in intron-1 of the gene, to be associated with lower plasma levels of LDL-C and a lower risk of CHD \[[@pone.0227779.ref035]\]. Data from the GLGC consortium suggested that *LDLR* rs6511720 minor allele is prevalent in about 10% of the population and have established that the allele is protective, being associated with lower levels of LDL-C \[[@pone.0227779.ref046]\].

Notwithstanding that, the frequency of recessive genes was low in this study population, these findings are consistent with previous reports by Wang et al., \[[@pone.0227779.ref019]\] and Aragones et al. \[[@pone.0227779.ref024]\] who did not find any significant differences in their studies with respect to prevalence of the DSCAML1 and ABCA1 genotypes. Our findings demonstrated that the allelic frequencies for ABCA1 and APOA5 polymorphisms were in not equilibrium with the Hardy-Weinberg equation among the case subjects as well as ABCA1 and DSCAML1 polymorphisms among the control subjects. The low frequencies of the homozygotes of the rare alleles of these SNPS may have contributed to the observed deviations.

A longitudinal study conducted by Rotgar et al. \[[@pone.0227779.ref047]\] validated the contribution of 42 SNPs to dyslipidemia among the HIV-infected population treated with ART. The authors reported that the degree of the contribution of SNPs and ART to dyslipidemia are similar and therefore genetic information should be considered in addition to the dyslipidemic effect of ART agents\[[@pone.0227779.ref047]\]. Results from the present study revealed that individuals with rs6511720 T/T genotype recorded increased levels of TC, TG, and LDL-C compared to the combination of non-carriers and heterozygous genotypes (GG/GT) \[[Table 3](#pone.0227779.t003){ref-type="table"}\]. A further multivariate logistic model analysis showed a strong association of LDLR polymorphisms with high levels of TC holding all other confounding variables constants. A study by Lazzaretti et al. \[[@pone.0227779.ref015]\] reported that *LDLR* intron 19G\>T (rs6511720) did not contribute to the plasma lipid levels in their dataset, and hence may reflect a limited effect of this SNPs in HIV-infected patients. The inconsistency could be due to different geographical settings and thereby calls for more research in these SNPs among African descendants.

In this study, ABCA1 (rs2066714) G/G genotype was associated with an increased probability of having dyslipidemia. Furthermore, subjects with the homozygotes of the rare alleles of ABCA1 have increased levels of TC compared to the common allelic (AA/AG) genotypes. As a further matter, subjects carrying the minor allelic variant of ABCA1 were more likely to have low levels of HDL cholesterol among the HIV population in the present study though no statistical significance was observed. These observations are congruent with previous reports demonstrated in literature that ABCA1 is associated with familial HDL deficiency. We should mention here that low HDL-C was one of the commonest lipid abnormalities observed in this study. Moreover, ABCA1 mediates the efflux of cellular cholesterol and phospholipids unto ApoA-I and thereby plays a central role in regulating cellular cholesterol homeostasis, and forming HDL\[[@pone.0227779.ref048], [@pone.0227779.ref049]\].

Individuals with T/T genotype for the *DSCAML1* (rs10892151) polymorphisms among the cases in this study had increased levels of TC, TG, and LDL-c compared with the other combined genotypes. Further analysis indicated that individuals with the homozygous minor recessive gene (carriers) (T/T) were more likely to have increased levels of TC and LDL-C. These observed findings are in parallel with previous reports by Aragones et al. \[[@pone.0227779.ref024]\] who reported a strong association between the expression of the rs10892151 T allelic variant and dyslipidemia, mostly hypertriglyceridemia and decreased HDL-cholesterol levels. In contrast, Pollin et al., \[[@pone.0227779.ref023]\] observed that rs10892151 T carriers had lower fasting and postprandial serum triglycerides values than non-carriers, and they found a linkage disequilibrium with an APOC3 null mutation, which was likely the result of a founder effect in their high-fat feeding intervention study. Evidence provided in the literature shows that carriers of this null mutation have low circulating apolipoprotein (Apo) C-III levels and reduced fasting and post-prandial triglyceride concentrations \[[@pone.0227779.ref023]\], which is likely due to the well-established function of Apo C-III as an inhibitor of lipoprotein lipase\[[@pone.0227779.ref050]\].

This current study showed that carriers of the minor allelic variant of the *APOA5* (rs662799) A\>G SNP gene, were 2 times more likely to developed dyslipidemia. Moreover, individuals with homozygotes (G/G) have significantly increased levels of TC and LDL cholesterol compared to wild type and heterozygote combined (AA/AG). Previous studies have found rs662799 to be associated with elevated plasma triglyceride levels as well as HDL-C and total cholesterol \[[@pone.0227779.ref021]\]. Two polymorphisms in the *APOA5* gene, −1131T\>C and S19W (56C\>G), have already been shown to be associated with elevated triglyceride levels in different populations\[[@pone.0227779.ref051], [@pone.0227779.ref052]\]. This study, however, considered the *APOA5* (rs662799) A\>G variant and found that HIV individuals with at least one G allele had higher TC and LDL cholesterol levels.

Lazzaretti et al. \[[@pone.0227779.ref015]\] reported that *APOA5* −1131T\>C (rs662799) was associated with plasma triglycerides (TG) and low-density lipoprotein cholesterol levels (LDL-C) as well as high-density-lipoprotein cholesterol levels. To the best of our knowledge, this study is the first to investigate the *APOA5* (rs662799) A\>G variant in HIV patients in a Ghanaian population. Another study by Echeverria et al. \[[@pone.0227779.ref053]\] reported that polymorphisms in genes associated with the development of atherogenic dyslipidemia, especially variants in the *APOA5* gene, can influence the circulating CD4 T-cell levels in chronically HIV-infected patients. Although a previous study has reported the effect of APOA5 on CD4 levels, individuals with the minor allelic variant of *APOA5* (rs662799) A\>G have a significant likelihood of developing dyslipidemia in HIV subjects on ART after controlling for CD4 counts as well as age, gender, duration of treatment and BMI.

This study has strength in it possibly being the first study to assess the prevalence of SNPs and their associations with dyslipidemia in the Ghanaian population as a proof of concept. Although previous reports have shown an uneven continuous rate of the incidence of HIV in the Ghanaian population with more than 60% of people living with HIV are females \[[@pone.0227779.ref054]\], the proportion of HIV- infected females in this study population was much higher than males which could affect the generalizations of our findings to the HIV population in Ghana. In addition, our study is limit by the fact that the number of investigated polymorphisms is not comprehensive, notwithstanding, this is a baseline study for future exploratory analysis of SNPs and their associations with dyslipidemia among HIV patients on ART in Ghana.

Conclusion {#sec016}
==========

This study has highlighted the evidence that SNPs in four candidate genes are present in HIV patients exposed to ART in the Ghanaian population. Dyslipidemia remains prevalent among HIV patients. SNPs were found to associate with dyslipidemia especially variants in APOA5-rs662799 and LDLR-rs651172 respectively. This finding provides baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated HIV patients Findings from this study should be validated in a longitudinal case-control study considering the disease and its therapeutic implications. These candidate SNPs if validated would help in serving as potential biomarkers to detect individuals at risk for dyslipidemia.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Though obviously suppressing HIV transmission and extending the life expectancy of HIV-infected patients, antiretroviral therapy (ART) also shows some side effects on human health. For example, long-term use of ART is associated with metabolic disturbances, such as dyslipidemia. In this study, the author studied the relationship of gene variants with dyslipidemia in HIV-infected patients receiving ART. Their data suggested that protease inhibitor treatment might be associated with higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides \[TG\], compared with other ART treatment. In addition, four SNPs from four genes (ABCA1, LDLR, APOA5, and DSCAML1) are associated with dyslipidemia in HIV-infected patients receiving ART.

Major issues:

1\. In the introduction, to easily make the reader understand the whole paper, the author had better explain why they selected these four SNPs to be studied.

2\. The author said "Significantly increased levels of total cholesterol (TC) low-density lipoprotein cholesterol (LDL-C) and triglycerides \[TG\] were observed in protease inhibitor-based (PI) treated case subjects compared to non-PI-based case subjects" in the abstract. However, the similar presentation is deficient in the result section. Please add the corresponding content in the result section.

3\. To make the reader better understand the relationship of different ART with dyslipidemia in HIV-infected patients, the author may as well describe the number of HIV-infected patients who receive PI or NNRTI.

Minor issues:

1\. In the first paragraph of the result section, "All but HDL-cholesterol levels were significant levels in the control subjects compared to case subjects \[ 1.44±0.33 vs. 0.99±0.53, p\<0.0001\]." should be "All but HDL-cholesterol levels were significantly lower levels in the control subjects compared to case subjects \[ 1.44±0.33 vs. 0.99±0.53, p\<0.0001\]."

2\. In Table 5, the author should clarify the definition of PRR in the sentence "DSCAML1 (T/T) \[PRR=11.46(3.65-43.56), p\<0.0001)".

Reviewer \#2: In the present study, Acheampong et al analyze the potential association of genetic variation in four different genes with the existence of dyslipidemia in HIV-infected patients on stable cART from Ghana.

Overall Major concern

The main concern of the study is that the design is very confusing. The authors state that the study is a case-control study. However there seems to be some confusion in the groups of selected individuals and their assignment to either cases or controls. In a case-control study, cases are those individual presenting the disease (in this case dyslipidemia) and controls are those not presenting the disease. The objective of the study (as stated by the authors) is to "..investigate the distribution of SNPs in four candidate genes and resultant association with plasma lipid levels in Ghanian HIV-infected patients on HAART". For this purpose cases should be HIV patients with dyislipidemia and controls HIV patients without dyslipidemia. However, the authors recruit a population of HIV-seronegative adults without dyislipidemia as controls (in the author's own words: "...alongside age-matched control subjects with no history of HIV, dyslipidemia, hypertension, and diabetes.."). In my opinion this is not the ideal control population as I have explained above. The inclusion of a population of individuals seronegative for HIV (with and without dyslipidemia) would serve to answer the question: Are the SNPs associated with dyslipidemia in the HIV population the same as those in the non-HIV population? However this is not the question that the objective addresses as the authors state (see above). Moreover, thereafter in the results section, the authors report that 18,3% of controls (ie. HIV-seronegative individuals) presented dyslipidemia. Thus there is a contradiction between the results and the inclusion criteria for the control population ("age-matched control subjects with no history of HIV, dyslipidemia, hypertension, and diabetes"). Also, the only data given for the control population is the prevalence of dyslipidemia and the distribution of allelic and genotypes frequencies for the different SNPs, but no data are given about the association of SNPs and dyslipidemia in this control population. Lastly, there is no discussion at all about the findings in the HIV-seronegative ("control") population. Thus what is the reason to include this "control" population?.

In summary the authors must clarify this and explain the reason to include the "control" (HIV-seronegative individuals) population.

Specific concerns

1.- Introduction:

.- Some references are not the most adequate, for example references \#3-5, reference \#1 (this reference is very old), reference \#19, references \#21-22. The authors should change these references for other more appropriate references.

.- The last sentence of the second paragraph ("Specifically, a direct association has been observed between...") should not be included here. This sentence is about the association between lipid levels and clinical endpoints, but in the previous sentence the authors are commenting about the association between genetic variation and metabolic dysfunction.

-. In the last paragraph the authors state that "...numerous SNP-associated dyslipidemia studies among HIV patients have come from non-African countries \[18, 24, 25\]". However this is not true since the reference \#24 is a study performed in a cohort of HIV patients from Zimbabwe.

2.- Materials and methods

.- In the section of sample size determination the authors assume an expected proportion of 0.1. Are there any previous study supporting this figure?.

.- In the data collection and biochemical analysis section the authors state that patients with triglycerides levels above 4.52 nmol/L were excluded from the study. The authors should explain to what extent this fact may impose a selection biass on the study population.

3.- Results

.- The proportion of females is much higher that the proportion of males. Is there any specific reason for this? Is this representative of the genre distribution among the HIV population in Ghana?. Moreover, the females proportion in the HIV-infected population is so high that the results obtained regarding the association between SNPs and dyslipidemia do really apply to only the female genre. The authors should discuss this fact and include it as one of the limitations of the study.

.- In table 1, immunovirological data of HIV population should be included (CD4 counts, time on HAART, pre-HAART HIV plasma viremia, etc..).

.- In the paragraph commenting the results given in table 2 the authors state that there was a significant difference (p=0.021) between cases and controls for rs662799 G/G genotype. However this p-value (as it appears on the table) is for the comparison of the frequency of allelic distribution and not of C/C genotype distribution. This is very confusing. Moreover, the authors must also compare the genotypes distribution and not only the allelic distribution and include this data in the table 2. The authors do not explain the reason to compare the allelic and genotypes distribution between HIV-infected and HIV-seronegative population. They do not comment anything about this comparison in the discussion section of the manuscript.

.-Table 3: data for these parameters in the control (HIV-seronegative) population should be given.

.- The way data are given on table 4 is somewhat confusing and not easy to quickly understand. A more understandable way to give the data would be to report the proportion of dyslipidemia in each group of patients according to the different SNPs genotypes. Moreover, when commenting the results given in this table, the authors state that "subjects with T/T genotype for LDLR polymorphism had a prevalence of dyslipidemia 3.46 times greater than non-dyslipidemic subjects." Clearly this sentence makes no sense. Authors should pay more attention to the writing, since there are several errors either because a word is missing or because the word is not appropriate.

.- Data given in table 4 for HIV population should also be given for HIV-seronegative subjects.

.- Table 5: the authors report results from 3 different models. In each model the number of covariates differs, increasing from model 1 to model 3. Model 3 is the that includes the highest number of covariates and thus this is the only model that should be shown in table 5. In this table, the authors should include the definition of the terms: "Hypercholesterolemia", "Hypertriglyceridemia", "Low HDL-C", and "High LDL-C".

.- A table with the results of the multivariate logistic regression using dyslipidemia as the outcome variable should be included in the manuscript.

.-Supplementary data: a table comparing different characteristics between PI-base and NNRTI-based HAART regimens is shown as supplementary data. However there is no mention to this data in the text of the manuscript. The authors should briefly report in the text the findings of this supplementary data.

4.- Discussion

.- In the first sentence of the second paragraph the authors state that "the presence of..... among our study participants were very low.."Do the authors refer to the overall population of subjects included (HIV and HIV-seronegative together) of specifically to the HIV population. It is interesting that the prevalence of homozygous genotypes for the minor alleles (for ABCA1, DSCAML1 and APOA5 SNPs) is higher in HIV patients than in HIV-seronegative subjects, but the authors do not comment anything about this. They should discuss about this finding.

.- In the second sentence of the fifth paragraph the authors state that "This observation could be explained by the observation that almost half of the subjects carried the ABCA1 (rs2066714) G/G or A/G mutant......". This is interpretation is incorrect since G/G and A/G carriers represented 36.6% of the population and this figure is far from "almost half".

.- In the fourth sentence of the fifth paragraph the authors state that "In addition, Pollin et al.."In my opinion the sentence should start with "In contrast.." because the results of Pollin et al are different from the results reported in this manuscript.

.- In the first sentence of the sixth paragraph the word "homologous" has no sense at all. It must be changed to "homozygous". Also in this same paragraph the sentence "The rs662799 is a SNP in the APOA5 gene" is not necessary since this has been already explained before throughout the text.

English grammar comment: I strongly recommend the manuscript to be revised by a native English-speaker.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Dear Editor-In-Chief

Manuscript tittle: Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients in a Ghanaian population

Article \# PONE-D-19-22071

We sincerely thank the reviewers for the truly helpful comments to improve the quality of our manuscript. We have read through carefully, please find our detailed responses below each specific point

Reviewer \#1:

Though obviously suppressing HIV transmission and extending the life expectancy of HIV-infected patients, antiretroviral therapy (ART) also shows some side effects on human health. For example, long-term use of ART is associated with metabolic disturbances, such as dyslipidemia. In this study, the author studied the relationship of gene variants with dyslipidemia in HIV-infected patients receiving ART. Their data suggested that protease inhibitor treatment might be associated with higher levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides \[TG\], compared with other ART treatment. In addition, four SNPs from four genes (ABCA1, LDLR, APOA5, and DSCAML1) are associated with dyslipidemia in HIV-infected patients receiving ART.

Major issues:

Comment: In the introduction, to easily make the reader understand the whole paper, the author had better explain why they selected these four SNPs to be studied.

Response: The authors are grateful for the comment. We have provided extra information the four SNPS selected for the study, role in lipid metabolism and its relationship with lipid abnormities in the introduction section

Comment: The author said "Significantly increased levels of total cholesterol (TC) low-density lipoprotein cholesterol (LDL-C) and triglycerides \[TG\] were observed in protease inhibitor-based (PI) treated case subjects compared to non-PI-based case subjects" in the abstract. However, the similar presentation is deficient in the result section. Please add the corresponding content in the result section.

Response: Thank you for the comment. We have provided the information on the comparison of general characteristics of patient based on treatment type in the results section revised manuscript, as table was submitted as supplement table (s1. Table 1)

Comment: To make the reader better understand the relationship of different ART with dyslipidemia in HIV-infected patients, the author may as well describe the number of HIV-infected patients who receive PI or NNRTI.

Response: We have provided a table in the supplement information describing the number of HIV patients who received PI or NNRTI in the revised manuscript

Minor issues:

Comment: In the first paragraph of the result section, "All but HDL-cholesterol levels were significant levels in the control subjects compared to case subjects \[ 1.44±0.33 vs. 0.99±0.53, p\<0.0001\]." should be "All but HDL-cholesterol levels were significantly lower levels in the control subjects compared to case subjects \[ 1.44±0.33 vs. 0.99±0.53, p\<0.0001\]"

Response: We have revised this sentence in the new manuscript

Comment: In Table 5, the author should clarify the definition of PRR in the sentence "DSCAML1 (T/T) \[PRR=11.46(3.65-43.56), p\<0.0001)".

Response: Results have been restructured therefore section have been revised for proper clarification

Reviewer \#2:

In the present study, Acheampong et al analyze the potential association of genetic variation in four different genes with the existence of dyslipidemia in HIV-infected patients on stable cART from Ghana.

Overall Major concern

The main concern of the study is that the design is very confusing. The authors state that the study is a case-control study. However there seems to be some confusion in the groups of selected individuals and their assignment to either cases or controls. In a case-control study, cases are those individuals presenting the disease (in this case dyslipidemia) and controls are those not presenting the disease. The objective of the study (as stated by the authors) is to ". investigate the distribution of SNPs in four candidate genes and resultant association with plasma lipid levels in Ghanaian HIV-infected patients on HAART". For this purpose, cases should be HIV patients with dyislipidemia and controls HIV patients without dyslipidemia. However, the authors recruit a population of HIV-seronegative adults without dyislipidemia as controls (in the author's own words: "...alongside age-matched control subjects with no history of HIV, dyslipidemia, hypertension, and diabetes."). In my opinion this is not the ideal control population as I have explained above. The inclusion of a population of individuals seronegative for HIV (with and without dyslipidemia) would serve to answer the question: Are the SNPs associated with dyslipidemia in the HIV population the same as those in the non-HIV population? However, this is not the question that the objective addresses as the authors state (see above). Moreover, thereafter in the results section, the authors report that 18,3% of controls (ie. HIV-seronegative individuals) presented dyslipidemia. Thus, there is a contradiction between the results and the inclusion criteria for the control population ("age-matched control subjects with no history of HIV, dyslipidemia, hypertension, and diabetes"). Also, the only data given for the control population is the prevalence of dyslipidemia and the distribution of allelic and genotypes frequencies for the different SNPs, but no data are given about the association of SNPs and dyslipidemia in this control population. Lastly, there is no discussion at all about the findings in the HIV-seronegative ("control") population. Thus, what is the reason to include this "control" population? n summary the authors must clarify this and explain the reason to include the "control" (HIV-seronegative individuals) population.

Response: We are grateful for the comment which has enabled us to have a critical look at our manuscript. Since knowledge on presence of the SNPS was not known in the general population for the selected genes, authors deemed it relevant to established. This is to strengthen our findings in the HIV-infected recruited of the study. The HIV seronegative individual recruited did not initially have any history of dyslipidaemia, diabetes or any chronic disease as stated in the manuscript, however after the measurement of lipid parameters and used of the NCEP-ATP III criteria to diagnose for dyslipidaemia, 18.3% were found to be dyslipidaemic. Based on the comments from the reviewer, we excluded the 18.3% HIV seronegative individual with dyslipidaemia from the data analysis. To further strengthen our findings, the HIV infected population were categorised into two groups, thus those with dyslipidaemia and those without dyslipidaemia. Therefore, all statistical analyses were made in these three groups. HIV seronegative individual without dyslipidaemia were used as a referent in statistical comparisons and association in the revised manuscript.

Specific concerns

1\. Introduction:

Comment: Some references are not the most adequate, for example references \#3-5, reference \#1 (this reference is very old), reference \#19, references \#21-22. The authors should change these references for other more appropriate references.

Response: Thank you for the comments, we have updated our references as suggested by the reviewer.

Comment: The last sentence of the second paragraph ("Specifically, a direct association has been observed between...") should not be included here. This sentence is about the association between lipid levels and clinical endpoints, but in the previous sentence the authors are commenting about the association between genetic variation and metabolic dysfunction.

Response: Thank you for the comment, we have excluded the sentence as suggested in the revised manuscript

Comment: In the last paragraph the authors state that "...numerous SNP-associated dyslipidaemia studies among HIV patients have come from non-African countries \[18, 24, 25\]". However, this is not true since the reference \#24 is a study performed in a cohort of HIV patients from Zimbabwe.

Response: Thank you for comment, sentence has been revised as studies on SNPS are few compared to the advanced countries

2\. Materials and methods

Comment: In the section of sample size determination the authors assume an expected proportion of 0.1. Are there any previous study supporting this figure?

Response: Section has been revised; as it was based on previous report from a study conducted on the burden of dyslipidaemia among adults in Ghanaian a population and the lack of knowledge of the frequency of polymorphisms in the population. we speculate a value to give a strong statistical power.

Comment: In the data collection and biochemical analysis section the authors state that patients with triglycerides levels above 4.52 nmol/L were excluded from the study. The authors should explain to what extent this fact may impose a selection bias on the study population.

Response: Section has been revised. We did not include ppatients with triglycerides above 4.52 mmol/L in the study since LDL-C was not directly measured and due to the deficit of the Friedewald's equation, which overestimates LDL-C levels when triglycerides are high. This is to reduce any bias that might affect the relationship found between LDL-C and dyslipidaemia

3\. Results

Comment: The proportion of females is much higher that the proportion of males. Is there any specific reason for this? Is this representative of the genre distribution among the HIV population in Ghana? Moreover, the female's proportion in the HIV-infected population is so high that the results obtained regarding the association between SNPs and dyslipidemia do really apply to only the female genre. The authors should discuss this fact and include it as one of the limitations of the study.

Response: The authors are grateful for the comment. Previous reports have shown an uneven continuous rate of the incidence of HIV in the Ghanaian population with more than 60% of people living with HIV are females, nonetheless we have indicated in the revised manuscript as potential limitation.

Comment: In table 1, immunovirological data of HIV population should be included (CD4 counts, time on HAART, pre-HAART HIV plasma viremia, etc..).

Response: Section has been revised as CD4 counts has been included in the data analysis.

Comment: In the paragraph commenting the results given in table 2 the authors state that there was a significant difference (p=0.021) between cases and controls for rs662799 G/G genotype. However, this p-value (as it appears on the table) is for the comparison of the frequency of allelic distribution and not of C/C genotype distribution. This is very confusing. Moreover, the authors must also compare the genotypes distribution and not only the allelic distribution and include this data in the table 2. The authors do not explain the reason to compare the allelic and genotypes distribution between HIV-infected and HIV-seronegative population. They do not comment anything about this comparison in the discussion section of the manuscript.

Response: Thank you for the comment; we have restructured Table 2, where we have provided the Hardy-Weinberg equation (HWE)-p-value for the allelic frequency using HWE. Chi-square analysis has also been used to obtain p-value for the difference in genotype frequency in the different groups. Interpretation has been revised for clarity in the revised manuscript.

Comment: Table 3: data for these parameters in the control (HIV-seronegative) population should be given.

Response: The authors are grateful; data on the genotype in the HIV seronegative have been provided in the table in the revised manuscript

Comment: The way data are given on table 4 is somewhat confusing and not easy to quickly understand. A more understandable way to give the data would be to report the proportion of dyslipidemia in each group of patients according to the different SNPs genotypes. Moreover, when commenting the results given in this table, the authors state that "subjects with T/T genotype for LDLR polymorphism had a prevalence of dyslipidemia 3.46 times greater than non-dyslipidemic subjects." Clearly this sentence makes no sense. Authors should pay more attention to the writing, since there are several errors either because a word is missing or because the word is not appropriate.

Response: Thank you for the comment, Table has been restructured in the revised manuscript and interpretation has been done for clarity

Comment: Data given in table 4 for HIV population should also be given for HIV-seronegative subjects.

Response: Thank you for the comment; data on the genotype in the HIV seronegative have been provided in Table 4 in the revised manuscript.

Comment: Table 5: the authors report results from 3 different models. In each model the number of covariates differs, increasing from model 1 to model 3. Model 3 is the that includes the highest number of covariates and thus this is the only model that should be shown in table 5. In this table, the authors should include the definition of the terms: "Hypercholesterolemia", "Hypertriglyceridemia", "Low HDL-C", and "High LDL-C".

Response: Thank you for the comment, as suggested by the reviewer, we have reported model 3 in the revised manuscript which other confounding factors were adjusted for. The NCEP-ATP III criteria used to define dyslipidaemia provides the various cut-off for high TC, low HDL-C, high LDL-C A and high TG were provided in this manuscript

Comment: A table with the results of the multivariate logistic regression using dyslipidaemia as the outcome variable should be included in the manuscript.

Response: We have provided a graph for the multivariate logistic regression using dyslipidaemia as a dependable variable generated with R program

Comment: Supplementary data: a table comparing different characteristics between PI-base and NNRTI-based HAART regimens is shown as supplementary data. However, there is no mention to this data in the text of the manuscript. The authors should briefly report in the text the findings of this supplementary data.

Response: We have provided information on the supplement data on the table comparing different characteristics between PI-base and NNRTI-based HAART regimens

4\. Discussion

Comment: In the first sentence of the second paragraph the authors state that "the presence of... among our study participants were very low "Do the authors refer to the overall population of subjects included (HIV and HIV-seronegative together) of specifically to the HIV population. It is interesting that the prevalence of homozygous genotypes for the minor alleles (for ABCA1, DSCAML1 and APOA5 SNPs) is higher in HIV patients than in HIV-seronegative subjects, but the authors do not comment anything about this. They should discuss about this finding.

Response: Section has been revised in accordance with the reviewer comments.

Comment: In the second sentence of the fifth paragraph the authors state that "This observation could be explained by the observation that almost half of the subjects carried the ABCA1 (rs2066714) G/G or A/G mutant......". This is interpretation is incorrect since G/G and A/G carriers represented 36.6% of the population and this figure is far from "almost half".

Response: Thank you for the comment; section has been revised and proper interpretation has been done for clarity.

Comment: In the fourth sentence of the fifth paragraph the authors state that "In addition, Pollin et al." In my opinion the sentence should start with "In contrast" because the results of Pollin et al. are different from the results reported in this manuscript.

Response: Response: Thank you for the comment; section has been revised

Comment: In the first sentence of the sixth paragraph the word "homologous" has no sense at all. It must be changed to "homozygous". Also, in this same paragraph the sentence "The rs662799 is a SNP in the APOA5 gene" is not necessary since this has been already explained before throughout the text.

Response: Thank you for the comment; section has been revised

Comment: English grammar comment: I strongly recommend the manuscript to be revised by a native English-speaker.

Response: Thank you for the comment; section has been revised.
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Dear Mr Acheampong,

Thank you for submitting your revised manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a second revised version of the manuscript that addresses the points raised during the review process. Please pay attention to the issues raised by the Reviewer \#2, and properly answer her/his comments and revise the main text.

We would appreciate receiving your revised manuscript by Jan 13 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Yong-Gang Yao

Academic Editor
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The author has addressed all my questions. I don\'t have other major concerns. However, there is still a few minor issues. For example, in the introduction, \"Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role lipoprotein metabolism by mediating the uptake of cholesterol through

the binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins.\" should be \"Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role in lipoprotein metabolism by mediating the uptake of cholesterol through the binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins.\" So the author needs to proofread the whole manuscript carefully.

Reviewer \#2: The revised version of the manuscript by Acheampong et al is still very far from being suitable for publication, for the next reasons:

1.- The authors did not satisfactorily answer the overall major concern regarding the design of the study and the rationale to include HIV-seronegative individuals. This is a study about the influence of several SNPs in the presence of dyslipidemia in HIV-patients on HAART. So, unless there is a very clear and strong reason as I explained in my first revision, HIV-seronegative individuals must be excluded from the study.

I strongly recommend the authors to exclude the 104 HIV-seronegative individuals from the study and reanalyze the data again only with the 289 HIV-patients.

2.- The design of the study is not clear at all and authors must clarify this. Is this a case-control study? (in my opinion it is). I already explained in my first revision who are the cases and who are the controls in a case/control study. If the authors do not consider that this is a case/control study, then the use of the terms "study groups"; "HIV+Dys+"; "HIV+Dys-" is OK but all mention to "cases" and "controls" must be deleted from the manuscript.

I strongly recommend the help of a statistician.

3.- The way data are presented in tables 4 and 5 (logistic regression with diyslipidemia and with individual lipid abnormalities) and in figures 2 and 3, is incomprehensible. As the authors explain, the odds ratios shown in these tables and figures are referred to the "control" HIV-seronegative population. This is very difficult to understand. The clearest way to show evidence for association between the genotype of the different SNPs and the existence of dyslipidemia, is to calculate the odds ratios of having dyslipidemia in carriers of the minor homozygous genotype for each of the SNPs, taking the other individuals (carriers of the major homozygous and of the heterozygote genoypes) as reference (OR=1).

4.- The manuscript is still plagued with grammatical errors, sentences difficult to understand and words not appropriate, etc...

I strongly recommend that the whole manuscript is revised by a native English speaker

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

23 Dec 2019

Response to Editorial comments

Dear Editor-In-Chief

Manuscript tittle: Association of Single Nucleotide Polymorphisms with Dyslipidemia in Antiretroviral Exposed HIV Patients in a Ghanaian population

Article \# PONE-D-19-22071

We sincerely thank the reviewers for the truly helpful comments to improve the quality of our manuscript. We have read through carefully, please find our detailed responses below each specific point

Review Comments to the Author

Reviewer \#1:

Comment: The author has addressed all my questions. I don\'t have other major concerns. However, there is still a few minor issues. For example, in the introduction, \"Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role lipoprotein metabolism by mediating the uptake of cholesterol through the binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins.\" should be \"Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role in lipoprotein metabolism by mediating the uptake of cholesterol through the binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins.\" so the author needs to proofread the whole manuscript carefully.

Response: Thank you for the comment. Section has been revised and manuscript has reviewed by an English native speaker

Reviewer \#2:

The revised version of the manuscript by Acheampong et al is still very far from being suitable for publication, for the next reasons:

1\. Comment: The authors did not satisfactorily answer the overall major concern regarding the design of the study and the rationale to include HIV-seronegative individuals. This is a study about the influence of several SNPs in the presence of dyslipidemia in HIV-patients on HAART. So, unless there is a very clear and strong reason as I explained in my first revision, HIV-seronegative individuals must be excluded from the study.

I strongly recommend the authors to exclude the 104 HIV-seronegative individuals from the study and reanalyse the data again only with the 289 HIV-patients.

Response: Thank you for the comment, the authors are grateful. We have excluded the 104 HIV sero-negative individuals from the study population and then reanalyse the dataset for the 289 HIV patients

2.Comment: The design of the study is not clear at all and authors must clarify this. Is this a case-control study? (in my opinion it is). I already explained in my first revision who are the cases and who are the controls in a case/control study. If the authors do not consider that this is a case/control study, then the use of the terms "study groups"; "HIV+Dys+"; "HIV+Dys-" is OK but all mention to "cases" and "controls" must be deleted from the manuscript. I strongly recommend the help of a statistician.

Response: Thank you for the comment. We believed that base on the reviewer comment and it is case-control study, section has been revised. We have considered the study as case-control and therefore the terms "HIV+Dys+" and "HIV+Dys-" has been removed from the manuscript. A statistician was involved in analysing the data.

3\. Comment: The way data are presented in tables 4 and 5 (logistic regression with diyslipidemia and with individual lipid abnormalities) and in figures 2 and 3, is incomprehensible. As the authors explain, the odds ratios shown in these tables and figures are referred to the "control" HIV-seronegative population. This is very difficult to understand. The clearest way to show evidence for association between the genotype of the different SNPs and the existence of dyslipidemia, is to calculate the odds ratios of having dyslipidemia in carriers of the minor homozygous genotype for each of the SNPs, taking the other individuals (carriers of the major homozygous and of the heterozygote genotypes) as reference (OR=1).

Response: Thank you for the comments. Tables 4 and 5 have been revised based on the reviewer's comment. Figures 2 and 3 have removed. We have reanalysed the data by calculating the odd ratios taking into consideration the combination of the carriers of the major homozygous and the heterozygote genotypes as referent

4.Coment: The manuscript is still plagued with grammatical errors, sentences difficult to understand and words not appropriate, etc...I strongly recommend that the whole manuscript is revised by a native English speaker

Response: Thank you for the comment. Our manuscript has been reviewed and revised by two native English speakers.
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Dear Dr. Acheampong,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Yong-Gang Yao

Academic Editor

PLOS ONE
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Dear Dr. Acheampong:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Dr. Yong-Gang Yao

Academic Editor

PLOS ONE
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